Yahoo
Morningstar

Morningstar

•

Nov 06, 2026

Zoetis Inc.: Zoetis Earnings: Firm Executes Hard Pivot To Play Defense; Raising Our Fair Value Estimate

Symbols

ZTS

Sector(s)

Healthcare

Rating

Current Price

79.40

Fair Value

Economic Moat

Stewardship

Summary

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products.

Upgrade to begin using premium research reports and get so much more.

Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level

Upgrade

Analyst Profile

Debbie S. Wang

Senior Equity Analyst

Debbie Wang is a senior equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers the medical-device industry. Previously, she was an associate director of equity analysis for Morningstar, leading the healthcare team.Before joining Morningstar in 2002, Wang was a vice president and senior brand strategist for Leo Burnett. During her tenure at Leo Burnett, she led brand strategy on a variety of accounts, including Allstate, Amoco, McDonald/s, Heinz, Smucker’s, Pepto-Bismol, and Celebrex.Wang holds a bachelor’s degree in anthropology from Colgate University and a master’s degree in business administration from the University of Chicago Booth School of Business.

Mobilize your Website
View Site in Mobile | Classic
Share by: